The California State Assembly Health Committee unanimously voted to advance the Cancer Patients’ Bill of Rights (Senate Concurrent Resolution 11) to the full California Assembly.
MD Anderson Cancer Center and Hummingbird Bioscience have entered into a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.
COTA and MedStar Health have entered into a research partnership to accelerate scientific discovery and improve care for cancer patients.
A new study led by scientists from the International Agency for Research on Cancer shows that an estimated 741,000 new cases of cancer in 2020 were associated with alcohol consumption globally.
A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
A cancer survivorship study is focusing on Kentucky cancer survivors with any type of cancer, and comparing the results within the state.
Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone has received FDA approval for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, has received FDA approval for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
It’s safe to say that July 1 was a better than average day for Suresh S. Ramalingam.
The FY22 budget proposed by the White House doesn’t include sufficient funds to sustainably support NCI researchers, even though the proposal includes the largest ever funding increase for NIH, the American Association for Cancer Research said in a letter to House appropriators.
